Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Interviews

  • Interview with Prof. Paul Lorigan

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Clinical trials and real world evidence
    • The development of melanoma treatment in recent years
    • What does the future hold
    • Closing remarks and take home messages


     

  • Interview with Prof. Silvia Formenti

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Combining radiation therapy with immunotherapy : clinical translation
    • The advantages
    • Possible future applications in clinical practice
    • Towards individualized treatments: revisiting old tools from a different point of view
    • Closing remarks and take home messages
  • Interview with Prof. Samir Khleif

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Strategies and designs for combination immunotherapy
    • The combinations
  • Interview with Prof. Barbara Seliger

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Role of signal transduction and microRNAs on the immunogenity of melanoma cells
    • The aim of the study
    • Perspectives
    • Future steps
    • Closing remarks and take home messages
  • Interview with Prof. Jerome Galon

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • The Worldwide Immunoscore Consortium in the era of tumor immunotherapy
    • The immunoscore test
    • “Make the test become a standard” this is the goal of the consortium
    • Future steps to get the test validated
    • The test could have a positive financial impact on the Health costs
    • Closing remarks and take home messages
  • Interview with Prof. Michael Atkins

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Approaches for patients with BRAF mutant melanoma
    • BRAF inhibitor combined with MEK inhibitor
    • Immunotherapy
    • Current recommendations
    • Closing remarks and take home messages
  • Interview with Prof. Reinhard Dummer

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
    • The adverse reactions
    • Closing remarks and take home messages
  • Interview with Prof. Janis Taube

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • PD-L1 expression in tissue
    • At what point in melanoma genesis is PD-L1 expressed
    • Conclusions and future perspectives
    • Closing remarks and take home messages
  • Interview with Prof. Paolo Ascierto part 1

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Phase 3 trial vemurafenib vs. vemurafenib + cobimetinib
    • Present recommendations
    • Paving the way to individualized treatments
    • Closing remarks and take home messages
  • Interview with Prof. Paolo Ascierto part 2

    Melanomabridge - Advances in melanoma interviews

    Highlights:

    • Nivolumab improved survival vs. dacarbazine inpatients with untreated advanced melanoma
    • Evaluation response rate and survival according to PD-L1 status
    • Closing remarks and take home messages

Pages

Share

 

 

E-Alert

Register to our E-Alert to stay informed of new clinical research and cases published on this platform.

Featured videos

Watch the videos from Reinhard Dummer, Dirk Schadendorf, Veronique del Marmol and Christian Blank.

Search this site

Search form

EJC SOCIETY PARTNERS